Open AccessClinical trials for coronavirus disease 2019: What is being evaluated and what is not
Author(s) -
Yaseen M. Arabi,
A.M. Asseri,
Steve Webb,
John C. Marshall,
Mohamed S Al Moamary
Publication year - 2020
Publication title -
annals of thoracic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.639
H-Index - 33
eISSN - 1817-1737
pISSN - 1998-3557
DOI - 10.4103/atm.atm_99_20
Subject(s) - medicine , covid-19 , clinical trial , outbreak , pandemic , coronavirus , disease , randomized controlled trial , intensive care medicine , virology , infectious disease (medical specialty)
Since the report of the first case of coronavirus disease 2019 (COVID-19) in China in late December 2019, there have been 204 610 cases worldwide as of 18 March, 2020. As part of the response to this outbreak, there has been an impressive amount of research undertaken to better characterize the disease and to evaluate therapeutic options. By March 12, 2020, there are more than 382 studies registered in the clinical trials databases addressing COVID-19 including more than 80 randomized controlled trials.